Medical release archive

First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis with polyangiitis

Lokelma label update approved in China for patients with hyperkalaemia on chronic haemodialysis

Brilinta reduced the composite of stroke and death in patients with head and neck artery atherosclerosis who had an acute ischaemic stroke or transient ischaemic attack

Farxiga showed cardiovascular and renal benefit in patients with chronic kidney disease irrespective of cardiovascular disease status

Brilinta reduced subsequent disabling stroke or death in patients who had an acute ischaemic stroke or transient ischaemic attack in Phase III THALES trial sub-analysis

Anifrolumab reduces disease flares in patients with systemic lupus erythematosus while allowing oral corticosteroid tapering

Fasenra significantly reduced exacerbation rate for severe eosinophilic asthma patients in Phase IIIb ANDHI trial

AstraZeneca licenses preclinical porcupine inhibitor, RXC006, for idiopathic pulmonary fibrosis

Anifrolumab showed early and sustained treatment benefit for patients with systemic lupus erythematosus in the TULIP clinical trial programme

Lokelma label update approved in EU for patients with hyperkalaemia on stable haemodialysis